Novartis's replacement portfolio, Kisqali, Pluvicto, and Scemblix, showed increased sales growth of upto 79% in Q2 2025

Worldwide revenue (in millions USD) for the second quarter (Q2) of 2025, the first half (H1) of 2025, and 2024 for the top 10 Novartis-marketed drugs.

(Please use a modern browser to see the interactive version of this visualization)

Chart: © Phalguni Deswal, Drug and Device World (www.druganddeviceworld.com)Source: Novartis's financial disclosuresDownload imageCreated with Datawrapper